利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.016 秒)

    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR IMPROVED BACTERIAL ERADICATION
    2.
    发明公开
    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR IMPROVED BACTERIAL ERADICATION 审中-公开
    药物组合物和细菌的改进方法灭绝

    公开(公告)号：EP1968586A2

    公开(公告)日：2008-09-17

    申请号：EP06845116.0

    申请日：2006-12-08

    申请人： Advancis Pharmaceutical Corporation

    发明人： FLANNER, Henry, H. ,  GUTTENDORF, Robert, J. ,  CLAUSEN, Susan, P. ,  TREACY, Donald ,  BURNSIDE, Beth, A.

    IPC分类号： A61K31/43

    CPC分类号： A61K31/43

    摘要： Disclosed are once-a-day penicillin-type antibiotic products, comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, that are administered once-a-day in a dosage and for a number of days that provide a Total T>MIC that is sufficient to achieve at least the minimum amount of bacterial eradication for treatment of a bacterial infection. In one embodiment the products provide a T>MIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.

    MODIFIED RELEASE AMOXICILLIN PRODUCTS
    3.
    发明公开
    MODIFIED RELEASE AMOXICILLIN PRODUCTS 审中-公开
    与修饰释放AMOXICILLIN产品

    公开(公告)号：EP1969134A1

    公开(公告)日：2008-09-17

    申请号：EP06847542.5

    申请日：2006-12-08

    申请人： Advancis Pharmaceutical Corporation

    发明人： TREACY, Donald ,  POTTS, Alan R. ,  FLANNER, Henry H. ,  BURNSIDE, Beth A. ,  TOLLE-SANDER, Sanna ,  CLAUSEN, Susan P.

    IPC分类号： C12P21/04

    CPC分类号： A61K9/2081 ,  A61K9/5026 ,  A61K9/5084

    摘要： Disclosed are amoxicillin products comprising at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier. In some embodiments, when administered to a patient or subject in the fed state the amoxicillin products exhibit a pharmacokinetic profile for amoxicillin in the plasma characterized as follows: (1) the ratio of the portion of the AUC as measured from 2 hours post-administration to 5 hours post-administration to the portion of the AUC as measured from administration to 2 hours post- administration is at least 2.0: 1 : and (2) the ratio of the portion of the AUC as measured from 5 hours post-administration to 12 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 1.1:1. In additional embodiments the amoxicillin products exhibit a mean in-vitro dissolution profile within a defined range characterized as follows: 1) the percent dissolved at 0.25 hours is between 25 and 55 percent; 2) the percent dissolved at 0.5 hours is between 30 and 60 percent; 3) the percent dissolved at 1 hour is between 50 and 85 percent; 4) the percent dissolved at 1.5 hours is between 70 and 95 percent; and 5) the percent dissolved at 2 hours is at least 85 percent. In preferred embodiments the amoxicillin products exhibit both of these characteristics.